Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glasdegib TQT Study in Healthy Subjects
NCT03162900Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jun 2017
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of glasdegib in acute myeloid leukemia (AML) (4 arms), sponsored by Pfizer. Primary endpoint: QTcF interval. Started Jun 2017; status: completed.
02
Drugs
glasdegib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03162900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03162900.